Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study.
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Itani H, Endo T, Saito AM, Shibayama T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: shibayama t. JTO Clin Res Rep. 2023 Apr 6;4(6):100514. doi: 10.1016/j.jtocrr.2023.100514. eCollection 2023 Jun. JTO Clin Res Rep. 2023. PMID: 37304652 Free PMC article.
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: shibayama t. Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10. Cancer Immunol Immunother. 2021. PMID: 32648165 Free PMC article.
Erratum to: Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Hosokawa S, Ichihara E, Bessho A, Harada D, Inoue K, Shibayama T, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Hosokawa S, et al. Among authors: shibayama t. Jpn J Clin Oncol. 2021 Aug 1;51(8):1348. doi: 10.1093/jjco/hyab113. Jpn J Clin Oncol. 2021. PMID: 34215885 No abstract available.
Large-vessel vasculitis induced by pegfilgrastim and immune checkpoint inhibitor in a patient with small-cell lung cancer.
Shiraha K, Takigawa Y, Sato A, Fujiwara K, Matsuo Y, Goda M, Inoue T, Nakamura E, Fujiwara M, Matsuoka S, Watanabe H, Kudo K, Sato K, Shibayama T. Shiraha K, et al. Among authors: shibayama t. Respirol Case Rep. 2024 Feb 7;12(2):e01291. doi: 10.1002/rcr2.1291. eCollection 2024 Feb. Respirol Case Rep. 2024. PMID: 38328632 Free PMC article.
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Tabata M, Kozuki T, Ueoka H, Kiura K, Harita S, Tada A, Shibayama T, Takigawa N, Yonei T, Gemba K, Segawa Y, Kishino D, Tada S, Hiraki S, Tanimoto M; Okayama Lung Cancer Study Group. Tabata M, et al. Among authors: shibayama t. Cancer Chemother Pharmacol. 2007 Jun;60(1):53-9. doi: 10.1007/s00280-006-0346-y. Epub 2006 Sep 29. Cancer Chemother Pharmacol. 2007. PMID: 17009034 Clinical Trial.
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.
Takigawa N, Kiura K, Segawa Y, Watanabe Y, Kamei H, Moritaka T, Shibayama T, Ueoka H, Gemba K, Yonei T, Tabata M, Shinkai T, Hiraki S, Takemoto M, Kanazawa S, Matsuo K, Tanimoto M; Okayama Lung Cancer Study Group. Takigawa N, et al. Among authors: shibayama t. Br J Cancer. 2006 Nov 6;95(9):1142-4. doi: 10.1038/sj.bjc.6603422. Epub 2006 Oct 10. Br J Cancer. 2006. PMID: 17031394 Free PMC article.
351 results